Overview

Detailed Summary

Laurus Labs is a leading pharmaceutical and biotechnology company specializing in generic APIs and FDFs, with a strong focus on ARVs, oncology, and hepatitis treatments.
The company achieved a remarkable 30% revenue growth, reaching ₹5,001 crore, driven by strong performance in its CDMO and Generics divisions, demonstrating robust operational efficiency.
Significant capital investment occurred, with 15% of sales reinvested into expanding manufacturing capabilities, particularly in peptides and fermentation facilities.
Laurus Labs reported an impressive 388% increase in net profit for 9M FY26, attributed to improved product mix and operational leverage, leading to expanded EBITDA and gross margins.
The company is making strategic moves in biotechnology and advanced therapies, operationalizing gene therapy labs and actively investing in ADC capabilities, positioning itself in transformative health technologies.

Sector: Pharmaceuticals
Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln Lrg
Market Cap: 54,677 Cr
Volatility: High Risk
P/E Ratio: 64.7
Industry P/E: 26.3
PEG Ratio: 4.7
P/B Ratio: 11.4
52W High: 1,140.90
52W Low: 512.05

Sales CAGR

1Y: 10.18%
3Y: 3.49%
5Y: 13.28%
10Y: 12.50%

Profit CAGR

1Y: 110.69%
3Y: -20.25%
5Y: 7.33%
10Y: 11.34%

ROE

TTM: 14.23%
3Y: 10.25%
5Y: 16.66%
10Y: 15.40%

ROCE

TTM: 15.05%
3Y: 14.69%
5Y: 20.73%
10Y: 19.96%

Technicals

‌

Forecasts

Unlock Premium Features

Analyst Target, Price, EPS and Revenue Projections

Peers

Symbol	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
MANKIND	2080.00	85,946 Cr	46.21	5.62	0.00	11.45	12.34	6.26
AUROPHARMA	1184.00	68,819 Cr	19.47	1.96	0.00	9.77	12.69	6.63
ALKEM	5475.55	65,525 Cr	27.26	4.91	0.82	17.69	18.13	11.95
GLENMARK	2028.90	57,325 Cr	21.15	5.98	0.12	26.24	30.84	5.60
LAURUSLABS	1011.10	54,677 Cr	64.73	11.38	0.12	14.23	15.05	8.94
IPCALAB	1507.30	38,056 Cr	36.26	5.12	0.27	13.33	17.89	7.73
PPLPHARMA	164.30	21,840 Cr	—	2.70	0.08	-0.29	4.50	-1.01

Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

Ask AI

Consolidated Quarterly Results (in ₹ Crores)

View Standalone

Total Figures

QoQ Changes

Total Figures

	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Sales	1,224	1,195	1,440	1,195	1,224	1,415	1,720	1,570	1,653	1,778
Expenses	1,037	1,014	1,198	1,024	1,045	1,130	1,300	1,187	1,250	1,298
Operating Profit	188	181	241	171	178	285	421	382	403	480
OPM %	15.34	15.18	16.77	14.33	14.57	20.15	24.45	24.35	24.39	27.00
Other Income	1.78	2.43	19	2.51	4.60	9.42	59	10	27	5.76
Interest	42	51	51	49	53	58	56	52	40	39
Depreciation	93	98	102	106	108	106	110	117	120	121
Profit Before Tax	54	35	107	18	23	131	312	224	270	327
Tax %	27.04	27.30	29.78	33.86	22.31	30.66	25.12	28.16	28.17	22.49
Net Profit	39	25	75	12	18	91	234	161	194	253
EPS in Rs	0.68	0.43	1.40	0.23	0.37	1.71	4.33	3.02	3.61	4.65

Consolidated Profit Loss (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	1,932	2,069	2,292	2,832	4,814	4,936	6,041	5,041	5,554	5,929
Expenses	1,497	1,643	1,936	2,267	3,263	3,513	4,448	4,263	4,499	4,662
Operating Profit	435	426	356	565	1,551	1,422	1,592	777	1,055	1,266
OPM %	22.50	20.60	15.53	19.94	32.22	28.82	26.36	15.42	19.00	21.36
Other Income	32	29	16	5.92	24	15	6.00	26	75	83
Interest	100	80	88	90	68	102	165	183	216	218
Depreciation	106	125	164	187	205	251	324	385	430	441
Profit Before Tax	234	237	120	294	1,301	1,084	1,109	236	484	690
Tax %	18.73	29.40	21.70	13.06	24.39	23.20	28.16	28.83	26.82	27.07
Net Profit	190	168	94	255	984	832	797	168	354	503
EPS in Rs	9.66	3.09	1.73	1.17	15.64	15.27	14.59	2.96	6.63	15.60
Dividend Payout %	7.22	9.52	17.05	52.19	10.94	13.03	13.66	26.94	18.07	—

Consolidated Balance Sheet (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	16	106	106	106	107	107	107	108	108	108
Reserves	774	1,225	1,377	1,452	1,663	2,490	3,244	3,930	4,003	4,365
Borrowings	1,008	769	900	943	978	1,482	1,777	2,015	2,577	2,764
Other Liabilities	426	554	634	830	1,002	1,671	1,840	1,608	1,699	2,099
Total Liabilities	2,224	2,653	3,017	3,331	3,750	5,751	6,968	7,660	8,387	9,336
Fixed Assets	1,021	1,230	1,481	1,629	1,726	2,171	2,652	3,409	3,890	4,123
CWIP	70	143	163	110	67	362	813	551	423	458
Investments	7.05	3.41	3.41	3.41	3.41	3.41	31	50	124	233
Other Assets	1,126	1,277	1,369	1,589	1,953	3,214	3,472	3,651	3,950	4,521
Total Assets	2,224	2,653	3,017	3,331	3,750	5,751	6,968	7,660	8,387	9,336

Consolidated Cash Flows (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity	182	332	342	298	347	733	911	994	666	602
Cash from Investing Activity	-312	-289	-384	-253	-221	-941	-914	-996	-822	-682
Cash from Financing Activity	103	-54	42	-45	-128	255	30	-27	250	39
Net Cash Flow	-27	-10	0.59	0.02	-1.37	47	27	-29	93	-41

Shareholdings

Shareholding History

Quarterly

Yearly

Quarterly

	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Promoters	27.20%	27.20%	27.20%	27.19%	27.19%	27.18%	27.18%	27.60%	27.62%	27.59%	27.59%	27.49%
FIIs	22.42%	22.52%	24.03%	25.39%	25.97%	25.67%	26.08%	25.56%	25.52%	25.70%	26.16%	26.52%
DIIs	9.74%	10.35%	11.01%	11.14%	11.77%	13.56%	13.05%	12.74%	11.77%	11.94%	11.73%	12.43%
Public	40.64%	39.93%	37.76%	36.29%	35.07%	33.59%	33.69%	34.10%	35.09%	34.77%	34.51%	33.56%
Total Shareholders	4,18,615	4,17,977	4,02,640	3,82,880	3,56,830	3,24,059	3,09,063	2,92,214	2,92,905	2,80,223	2,83,678	2,80,756

Market Transactions

Unlock Premium Features

Analyst Target, Price, EPS and Revenue Projections

Projection

Unlock Premium Features

Get In-depth insights on EPS and Revenue forecasts

Documents

Presentations

Concalls

Reports

Presentations

Investor Presentation

Q3 FY26

Investor Presentation

Q2 FY26

Investor Presentation

Q1 FY26

Investor Presentation

Q4 FY25

Available on Pro Plan

Unlock reports, presentations, and AI-powered insights.

Investor Presentation

Q3 FY25

Available on Pro Plan

Unlock reports, presentations, and AI-powered insights.

Investor Presentation

Q3 FY25

Available on Pro Plan

Unlock reports, presentations, and AI-powered insights.

Investor Presentation

Q2 FY25

Available on Pro Plan

Unlock reports, presentations, and AI-powered insights.

Investor Presentation

Q1 FY25

Showing 1 - 8 of 40

Actions

Action Type

‌
‌

Announcements

Last 7 days

Newest

Sentiment

Sorry, no results found!

AI Mode

Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.

Ask AI

Frequently Asked Questions about Laurus Labs Ltd

Laurus Labs Ltd (LAURUSLABS) is currently trading at 1,014.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Laurus Labs is a leading pharmaceutical and biotechnology company specializing in generic APIs and FDFs, with a strong focus on ARVs, oncology, and hepatitis treatments. The company achieved a remarkable 30% revenue growth, reaching ₹5,001 crore, driven by strong performance in its CDMO and Generics divisions, demonstrating robust operational efficiency. Significant capital investment occurred, with 15% of sales reinvested into expanding manufacturing capabilities, particularly in peptides and fermentation facilities. Laurus Labs reported an impressive 388% increase in net profit for 9M FY26, attributed to improved product mix and operational leverage, leading to expanded EBITDA and gross margins. The company is making strategic moves in biotechnology and advanced therapies, operationalizing gene therapy labs and actively investing in ADC capabilities, positioning itself in transformative health technologies.

Over the past 52 weeks, Laurus Labs Ltd has traded between a low of ₹512.05 and a high of ₹1,140.90. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Laurus Labs Ltd has a market capitalization of approximately 54,676.67. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Laurus Labs Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 64.73 and operates in the Pharmaceuticals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 54,676.67 Cr, Laurus Labs Ltd is classified as a Mid Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Laurus Labs Ltd operates in the Pharmaceuticals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Laurus Labs Ltd is 64.73. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

The 'Biopharma Shakti' scheme, with a ₹10,000 crore outlay over five years, is the most significant announcement. It directly supports Laurus Labs' strategic investments in biologics, biosimilars, and its Bio division.

Laurus Labs reported a 173% year-on-year increase in net profit to Rs 252 crore. Revenue grew by 26% to Rs 1,778 crore, and the EBITDA margin expanded significantly to 27.3%.

In Q3 FY26, Laurus Labs reported a 174% year-on-year increase in consolidated net profit to ₹252 crore. Revenue from operations grew by 26% to ₹1,778 crore, and EBITDA surged by 70% to ₹485 crore.

Laurus Labs Ltd

Stock Summary and Key Metrics

Investment Checklist

Investment Checklist

Overview

Financial Ratios

Technicals

Forecasts

Unlock Premium Features

Upgrade

Peers

Price Chart Comparison

Financial Statements

AI Powered Summary

Ask AI

Consolidated Quarterly Results (in ₹ Crores)

Consolidated Profit Loss (in ₹ Crores)

Consolidated Balance Sheet (in ₹ Crores)

Consolidated Cash Flows (in ₹ Crores)

Shareholdings

Shareholding History

Market Transactions

Unlock Premium Features

Upgrade

Projection

Unlock Premium Features

Upgrade

Documents

Actions

Announcements

AI Mode

Ask AI

Frequently Asked Questions about Laurus Labs Ltd

What is Laurus Labs Ltd share price today?

What does Laurus Labs Ltd do?

What is the 52-week high and low of Laurus Labs Ltd?

What is the market capitalization of Laurus Labs Ltd?

Should I consider investing in Laurus Labs Ltd stock?

Is Laurus Labs Ltd a large-cap, mid-cap, or small-cap stock?

Which sector does Laurus Labs Ltd belong to and why does it matter?

What is the PE ratio of Laurus Labs Ltd?

What is the single biggest announcement in Union Budget 2026 for Laurus Labs?

What were the key highlights of Laurus Labs' Q3 FY26 results?

What were Laurus Labs' key financial highlights in Q3 FY26?

Utility

Company

Technicals

Forecasts

Unlock Premium Features

Upgrade

Projection

Unlock Premium Features

Upgrade

Frequently Asked Questions about Laurus Labs Ltd

What is Laurus Labs Ltd share price today?

What does Laurus Labs Ltd do?

What is the 52-week high and low of Laurus Labs Ltd?

What is the market capitalization of Laurus Labs Ltd?

Should I consider investing in Laurus Labs Ltd stock?

Is Laurus Labs Ltd a large-cap, mid-cap, or small-cap stock?

Which sector does Laurus Labs Ltd belong to and why does it matter?

What is the PE ratio of Laurus Labs Ltd?

What is the single biggest announcement in Union Budget 2026 for Laurus Labs?

What were the key highlights of Laurus Labs' Q3 FY26 results?

What were Laurus Labs' key financial highlights in Q3 FY26?

Oscillators

Bearish

Overall

Bullish

Moving Averages

Bullish

Overall

Bullish

Announcements

Peers

Price Chart Comparison

Overview

Financial Ratios

Investment Checklist